Previous 10 | Next 10 |
ACTON, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD ), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced the first FDA-cleared hair test for cotinine, the predominant metabolite for nicotine. This test p...
ACTON, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) will hold its Annual Meeting of Stockholders (“Annual Meeting”) on Thursday, May 14, 2020 at 2:00 p.m. ET. The meeting, which will be held in a virtual format only, will be webcast to the p...
ACTON, Mass., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2019. The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of rec...
ACTON, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today issued a response to a Massachusetts Supreme Judicial Court ruling in the case of Boston Police Department v. The Massachusetts Civil Service Commission, which dealt with the Boston Police Departme...
Psychemedics (NASDAQ: PMD ): Q3 GAAP EPS of $0.12. More news on: Psychemedics Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
ACTON, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2019. The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of Nov...
ACTON, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) announced today that it has entered into a new distribution agreement in Brazil with Sansão Holding S.A. and with Toxicologia Pardini Ltda., our existing independent distributor in Brazil, formerly k...
Psychemedics (NASDAQ: PMD ): Q2 GAAP EPS of $0.14. More news on: Psychemedics Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
ACTON, Mass., July 23, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2019. The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of August ...
Psychemedics ( PMD ) focuses on its patented hair-based drug-testing system. The drug and alcohol testing market is a $6 billion market that is expected to grow at a high single-digit rate in the coming years. The two general macro drivers behind the expectation include stricter legal environm...
News, Short Squeeze, Breakout and More Instantly...
Psychemedics Corporation Company Name:
PMD Stock Symbol:
NASDAQ Market:
Psychemedics Corporation Website:
DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a comprehensive analysis of drug trends in the workplace, drawing insights from a...
DALLAS, May 14, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2024. The Company’s revenue for the quarter ended March 31,...
DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023. “2023 proved to be another challenging year due to the nega...